What ails the FDA?

N Engl J Med. 2005 Mar 17;352(11):1063-6. doi: 10.1056/NEJMp058003.
No abstract available

MeSH terms

  • Administrative Personnel
  • Adolescent
  • Antidepressive Agents / adverse effects
  • Cyclooxygenase Inhibitors / adverse effects
  • Drug Approval / economics
  • Drug Approval / legislation & jurisprudence
  • Drug Approval / organization & administration*
  • Drug Industry / economics
  • Drug Industry / legislation & jurisprudence
  • Fees and Charges / legislation & jurisprudence
  • Government Regulation
  • Humans
  • Lactones / adverse effects
  • Product Surveillance, Postmarketing
  • Sulfones / adverse effects
  • Time Factors
  • United States
  • United States Food and Drug Administration / legislation & jurisprudence
  • United States Food and Drug Administration / organization & administration*

Substances

  • Antidepressive Agents
  • Cyclooxygenase Inhibitors
  • Lactones
  • Sulfones
  • rofecoxib